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Abstract
Background: Stroke prevention is the main goal of treating patients with atrial fibrillation (AF). Vitamin-K antagonists (VKAs)
present an effective treatment in stroke prevention, however, the risk of bleeding and the requirement for regular
coagulation monitoring are limiting their use. Apixaban is a novel oral anticoagulant associated with significantly lower
hazard rates for stroke, major bleedings and treatment discontinuations, compared to VKAs.
Objective: To estimate the cost-effectiveness of apixaban compared to VKAs in non-valvular AF patients in the Netherlands.
Methods: Previously published lifetime Markov model using efficacy data from the ARISTOTLE and the AVERROES trial was
modified to reflect the use of oral anticoagulants in the Netherlands. Dutch specific costs, baseline population stroke risk
and coagulation monitoring levels were incorporated. Univariate, probabilistic sensitivity and scenario analyses on the
impact of different coagulation monitoring levels were performed on the incremental cost-effectiveness ratio (ICER).
Results: Treatment with apixaban compared to VKAs resulted in an ICER of J10,576 per quality adjusted life year (QALY).
Those findings correspond with lower number of strokes and bleedings associated with the use of apixaban compared to
VKAs. Univariate sensitivity analyses revealed model sensitivity to the absolute stroke risk with apixaban and treatment
discontinuations risks with apixaban and VKAs. The probability that apixaban is cost-effective at a willingness-to-pay
threshold of J20,000/QALY was 68%. Results of the scenario analyses on the impact of different coagulation monitoring
levels were quite robust.
Conclusions: In patients with non-valvular AF, apixaban is likely to be a cost-effective alternative to VKAs in the Netherlands.
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Introduction
Atrial fibrillation (AF) is a heart disease common among elderly
people. In the Netherlands incidence rates increase with advancing
age from approximately 1% among 55-year olds to 18% among
85-year olds and related relevant risks of ischemic stroke (IS) and
other systemic thromboembolic events [1], [2]. In addition,
patients with AF suffer not only from a greater activity impairment
and lower quality of life (QoL) compared to the general population
but also have a 50–90% increased risk of mortality [3], [4]. The
majority of AF patients suffer from non-valvular AF. Strokes
related to AF are often characterized by more severe disability and
impairment of QoL in comparison to strokes due to other causes
[5]. As a result, stroke related morbidity, which is driven by high
hospitalization and long-term maintenance costs, causes a high
economic burden to the Dutch health care system. Specifically, the
6-month cost of usual care for stroke patients range from J16,000
to J54,000 depending on severity [6]. In parallel, the annual costs
of treating patients with AF in the Netherlands were estimated to
mount up to J2,328 with 70.1% of the resources allocated to the
inpatient care and interventional procedures [7]. Given the
humanistic implications of both AF and stroke and economic
considerations of their management, stroke prevention is the main
focus of treatment strategies for patients with AF and could be
expected to lead to both health and economic benefits.
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Until recently patients with AF and an estimated moderate to
high risk of stroke (i.e. cardiac failure, hypertension, age, diabetes,
stroke (doubled) [CHADS2] score $2) were recommended to
receive vitamin-K antagonists (VKAs; e.g. warfarin, acenocou-
marol or phenprocoumon) for stroke prevention [8]. However,
although VKAs present a highly effective treatment strategy in
reducing the incidence of stroke, their optimal effectiveness and
safety is crucially safeguarded with regular coagulation monitoring
due to VKAs’ narrow therapeutic range (international normalized
ratio [INR] limits of 2.0 and 3.0) [9]. Failure to achieve the
anticoagulant effect inside the required INR therapeutic range
increases the risk of IS and bleeding including hemorrhagic stroke
(HS). The complexity of regular monitoring, which in the Dutch
healthcare system is handled by thrombotic services, possibly
followed by failure to achieve the safety range inside INR limits,
accompanied with multiple drug and food interactions, might lead
to underuse of VKAs or even result in an increase in medication-
related hospital admissions as observed in HARM study [8], [10].
Recently, a new class of anticoagulants became available (novel
oral anticoagulant (NOAC)) that are at least as effective or
superior in reducing the risk of stroke or systemic embolism (SE),
have a better efficacy/safety profile and exclude the need for
constant INR monitoring, compared to VKAs [11–13]. Accord-
ingly, NOACs have been included in both international and
national guidelines [8], [14]. One of them is apixaban, a NOAC of
which the efficacy and safety was tested in clinical trials on VKA
suitable (ARISTOTLE trial [ClinicalTrials.gov Identifier,
NCT00412984]) or unsuitable (AVERROES trial [ClinicalTrials.-
gov Identifier, NCT00496769]) non-valvular AF patients with a
high risk of stroke [11], [15]. In the AVERROES trial, apixaban
was shown to prevent more stroke or SE events with no significant
difference in the incidence of major bleedings (MBs) or intracra-
nial hemorrhages (ICHs) compared to acetylsalicylic acid (ASA)
[15]. Similarly, in the ARISTOTLE trial, less stroke or SE events,
less MBs and less fatal events related to any cause were observed in
the treatment with apixaban when compared to the treatment
with VKA [11]. Despite obvious advantages of the NOACs, the
choice of the optimal treatment strategy for AF-patients always
needs to be made with respect to both health and economic
consequences of the approach chosen, including a formal
comparison of apixaban and VKAs as one element [16].
The aim of this study is to evaluate the health and economic
consequences of applying apixaban compared to VKAs for stroke
prevention in non-valvular AF patients in the Netherlands. The
health consequences associated with the use of apixaban and
VKAs reflecting the likelihoods of having stroke, other thrombo-
embolic or bleeding events, are mainly based on the data from the
ARISTOTLE trial [11]. The cost estimates of stroke and other
AF-related complications as well as drug costs, reflect the Dutch
situation from the healthcare payers’ perspective.
Methods
Decision model
Previously published lifetime Markov model was modified and
updated to reflect the use of apixaban per defined daily dose and
Figure 1. Model for the non-valvular AF population. Depicted in the diagram are the chance nodes (circles) and terminal nodes (triangles).
Branches for apixaban and VKA are identical except numerical risks. Patients that discontinue the initial anticoagulant treatment re-enter the model
with identical Markov branches but under the assumption of switching their treatment to acetylsalicylic acid. NVAF, non-valvular atrial fibrillation;
ASA, acetylsalicylic acid; IS, ischemic stroke; HS, hemorrhagic stroke; SE, systemic embolism; MI, myocardial infarction; ICH, intracranial hemorrhage;
CRNM, clinically-relevant non-major; MB, major bleeding; Tmt, treatment.
doi:10.1371/journal.pone.0103974.g001
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adjusted-dose warfarin in patients with non-valvular AF in the
Netherlands [17], [18]. The following health states were included
in the model: baseline (non-valvular AF), IS, HS, SE, myocardial
infarction (MI), other ICH, other MB and clinically-relevant non-
major (CRNM) bleeding, other treatment discontinuation and
death (Figure 1). Notably, other treatment discontinuations reflect
discontinuations that are not directly related to having had a
thrombotic or bleeding event. For the purposes of this study,
warfarin, studied versus apixaban in the ARISTOTLE trial [11],
was used as a comparator, as the Dutch reimbursement authorities
presume the efficacy and safety profile of warfarin and
acenocoumarol/phenprocoumon (also VKAs) to be interchange-
able [19].
Base-case analysis followed a cohort of 1,000 patients with non-
valvular AF whose characteristics were comparable to those in the
ARISTOTLE trial. Specifically, patients were predominantly
male, aged 70 years, with an average CHADS2 score of 2.3 and a
history of previous VKA use (Table 1) [11], [20], [21]. The
progression of patients with non-valvular AF through the Markov
model is detailed elsewhere [17], [18]. Briefly, patients remained
in the baseline state until a fatal or non-fatal event or treatment
discontinuation occurred, or they died due to other, non-
cardiovascular related, causes. In order to reflect daily life more
closely, a distinction between different levels of IS and HS severity
was made in the model, i.e. mild, moderate, severe and fatal. The
model allows one recurrent stroke event to occur. The annual risk
of recurrent stroke event was based on the 10-year cumulative risk
of recurrence derived from a population based study using the
South London stroke registry [22]. Health states for thromboem-
bolic events other than stroke (i.e. SE and MI) were considered to
be absorbing (i.e. patients remain there until death). The
probability of patient being in a particular health state was
assessed every 6-weeks which was the cycle length of the model.
Certain assumptions on the treatment following thromboem-
bolic or bleeding events were made. Firstly, upon the occurrence
of IS or SE, patients surviving were assumed to stay on the initially
assigned anticoagulant treatment while those surviving HS and MI
were assumed to only to receive long-term disease-specific
maintenance treatment. Secondly, patients experiencing other
ICH, MB and CRNM bleeding were allocated between an option
to stay on the initially assigned treatment and an option to switch
to ASA. Details on the allocation of patients between the two
treatment options are provided in previously published studies
[17], [18]. Patients staying on the initially assigned anticoagulant
treatment after an ICH that was not a HS, were additionally
assumed to have a six-week drug holiday. Finally, patients
discontinuing the initial treatment for reasons unrelated to stroke,
SE and bleeding were assumed to switch to ASA.
The final outcome of the decision model is the incremental cost-
effectiveness ratio (ICER) of apixaban compared to VKA. As a
measure of effectiveness, quality-adjusted life-years (QALYs) and
life years (LYs) gained were estimated. All relevant costs
incorporated in the model reflect the health care payer’s
perspective and were inflated to price year 2013 using the Dutch
consumer price index [23]. Future costs and health effects were
discounted by 4% and 1.5% annually after the first year, according
to the Dutch guidelines for pharmacoeconomic research [24].
Transition probabilities
Data from the ARISTOTLE and the AVERROES trial were
the main sources used to estimate the transition probabilities
between the health states in the model for patients receiving
apixaban, VKA and ASA [11], [15], [17], [18]. Specifically, the
rates of IS, MI, SE, ICH, other MB and CRNM bleeding and
other treatment discontinuations from the aforementioned trials,
were applied for deriving the transition probabilities between the
health states similarly to previously published Markov models
(Table S1) [17], [18]. Additionally, trial rates of IS, ICH, other
MB and CRNM bleeding were adjusted for the average level of
risk dependent on the level of INR control in the Netherlands
represented by mean time in therapeutic range (TTR) (i.e. 72.48%
[21], [25]). ICHs were further differentiated into HSs and other
ICHs; other MBs were differentiated to those that were or were
not gastrointestinal (GI) by location. Details on the number of
patients experiencing one of the two types of ICHs, specific fatality
rates after stroke, MI, SE, ICH and other MB and the factors of
age-related increasing risk of stroke, bleeding (i.e. ICH, other MB
and CRNM bleedings) and MI are provided elsewhere [17], [18],
[26].
The average risk of IS in patients receiving apixaban and VKA,
was estimated as the joint probability of having an event associated
with a specific baseline population stroke risk represented by
CHADS2 score corrected for the average level of risk dependent
on INR control, and the probability of having an event associated
with the level of INR control in the Netherlands (Table 1) [21],
[25]. Baseline population stroke risk represented by CHADS2
Table 1. Baseline characteristics of the patients included in the model.
Characteristic Value Range Reference
Age 70 63–77 [11]
Gender (female, %) 35.3 34.1–36.5 [11]
CHADS2 (% of patients)
1 7 5.4–8.8 [20]
2 27 21.3–33.1 [20]
3 25 19.7–30.7 [20]
4 20 15.7–24.7 [20]
5 12 9.3–15 [20]
6 7 5.4–8.8 [20]
7 2 1.5–2.5 [20]
Average TTR in the Netherlands (%) 72.48 Fixed [21]
CHADS2, cardiac failure, hypertension, age, diabetes, stroke (doubled); TTR, time in therapeutic range.
doi:10.1371/journal.pone.0103974.t001
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Table 2. Stroke and other thromboembolic and bleeding complications and related costs within a hypothetical patient population

















-Mild, non-fatal 96.32 J1,429 J638 93.01 J1,379 J614
-Moderate, non-fatal 83.62 J3,285 J2,612 89.30 J3,563 J2,921
-Severe, non-fatal 32.86 J1,586 J643 34.31 J1,675 J699
-Fatal 30.36 J67 29.05 J64
Sum 243.15 J10,259 245.67 J10,915
Recurrent IS
-Mild, non-fatal 10.63 J149 J38 10.81 J152 J37
-Moderate, non-fatal 4.21 J161 J225 4.28 J165 J244
-Severe, non-fatal 1.61 J75 J49 1.63 J77 J52
-Fatal 3.61 J7 3.67 J8
Sum 20.06 J705 20.40 J735
HS
-Mild, non-fatal 4.86 J79 J41 5.64 J93 J49
-Moderate, non-fatal 7.78 J339 J333 5.70 J247 J241
-Severe, non-fatal 4.47 J226 J105 5.67 J295 J147
-Fatal 10.88 J25 17.68 J42
Sum 27.99 J1,147 34.69 J1,115
Recurrent HS
-Mild, non-fatal 0.29 J4 J1 0.29 J4 J1
-Moderate, non-fatal 0.40 J16 J18 0.40 J16 J16
-Severe, non-fatal 0.13 J6 J5 0.13 J6 J6
-Fatal 0.44 J1 0.44 J1
Sum 1.25 J51 1.25 J51
SE
-Non-fatal 24.10 J86 24.60 J88
-Fatal 2.50 J0 2.55 J0
Sum 26.60 J86 27.14 J88
Other ICH
-Non-fatal 11.72 J176 19.20 J303
-Fatal 1.75 J0 2.87 J0
Sum 13.47 J176 22.07 J303
Other MBs
-Non-fatal GI bleedings 78.14 J306 69.49 J274
-Non-fatal Non ICH or Non GI related
MBs
126.23 J496 123.45 J490
-Fatal 4.17 J0 3.94 J0
Sum 208.54 J802 196.88 J764
CRNM bleeding 314.94 J7 372.69 J9
MI
-Non-fatal 76.39 J283 J596 78.85 J295 J630
-Fatal 14.34 14.79
Sum 90.73 J879 93.64 J925
Other treatment discontinuation 647.58 652.08
Cost of anticoagulants J3,870 J365
Pharmacoeconomics of Apixaban for Stroke Prevention
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score was determined by weighting the risk for each categorization
of CHADS2 score by the proportion of patients within each group
of CHADS2 score in the Netherlands [20].
Published population based registries were used to estimate the
transition probabilities for recurrence of events [22]. The annual
risks for recurrent stroke events of 2.97 and 2.17 were assigned to
patients surviving first IS and HS, respectively [22]. The
distribution of stroke severity for recurrent stroke events was
assumed to be the same as that of the first stroke events in patients
treated with apixaban.
Mortality due to causes other than cardiovascular while on
apixaban and VKA, for the trial period, were based on data from
the ARISTOTLE trial [11]. Beyond the duration of the trial
period (1.8 years), age- and gender-adjusted mortality due to
causes other than cardiovascular, was obtained from Statistics
Netherlands [27–29]. In addition to the mortality due to causes
other than cardiovascular, an increase in mortality rates associated
with AF, strokes by severity level, MI and SE, was incorporated as
in previously published Markov models [17], [18].
Utilities
A utility score specific for patients with AF was applied to all
patients in the baseline health state of the model (Table S2) [30].
Upon the occurrence of stroke, MI or SE, utility scores were
adjusted to account for the level of utility for AF and comorbid
thromboembolic event jointly [30], [31]. Utility decrements
following the occurrence of a certain bleeding event were applied
additively for a specific time interval [32]. Finally, utility
decrements reflecting the use of VKA (warfarin), apixaban and
ASA were applied [32] [33].
Costs
Prices of apixaban, defined as price per defined daily dose
(265 mg), VKAs and ASA (100 mg) were taken from the official
Dutch price list (Z-index) (Table S3) [34]. Cost of VKA was
estimated as a weighted average cost of acenocumarol and
fenprocoumon based on their usage in the Netherlands (80%:20%,
respectively) [35]. In addition to anticoagulants’ costs, routine care
cost representing medical specialist fee was added to all treatment
alternatives and cost due to INR testing was added to treatment
with VKAs [24].
Acute care costs associated with clinical events (IS and HS with
different levels of severity, other ICH, other MB and CRNM
bleedings, SE, MI) were adopted from previous costing studies
conducted in the Netherlands and updated to the year 2013 using
the Dutch inflation index (Table S3) [6], [23], [36], [37]. Patients
surviving acute stroke and MI were assigned with long-term
maintenance costs [38].
Sensitivity analyses
Univariate sensitivity analyses were conducted in order to
inspect the effects of the uncertainty in key input parameters and
assumptions on the uncertainty in the final cost-effectiveness
outcome. Furthermore, a probabilistic sensitivity analysis (PSA)
was performed in order to simultaneously incorporate the
uncertainty around all parameters in the CE analysis. Key input
parameters in the deterministic analysis that were assumed
random variables in the PSA were: event rates, utilities and costs.
A gamma distribution was assigned to event rates, a beta
distribution to utilities and a log-normal distribution to cost
estimates. Results from the PSA were plotted on a CE plane and
transformed into CE-acceptability curves (CEACs).
Finally, in order to investigate the impact of different levels of
INR control on the estimated ICER, as is the case in the various
Dutch thrombotic centers, scenario analyses were conducted. Four
different scenarios were investigated. Specifically, one scenario
assumed patients were equally distributed across centers with
different cTTR, similarly to the patient allocation in the
ARISTOTLE trial. Other scenarios assumed the allocation of
all patients to the one of specific cTTR range (i.e. cTTR,52.38%,
52.38%#cTTR,66.02% and cTTR$76.51%) that was different
from the range in the base-case analysis (i.e. cTTR=72.48%).
Results
The number of events associated with the use of VKAs and
apixaban in a cohort of 1,000 patients with non-valvular AF, as
well as the costs related to those events and the anticoagulant
treatment, are presented in Table 2. Specifically, the incremental
difference in the number of events observed over a lifetime horizon
in the apixaban treatment scenario compared to the VKA
treatment scenario was: ten less stroke or SE events (including
first and recurrent IS and HS), nine less other ICHs, 12 more
other MBs, three less MIs and 58 less CRNM bleedings. A
comparable number of other treatment discontinuations was
observed in both apixaban and VKA treatment scenarios (648 and
652 respectively). Finally, treatment with apixaban was estimated
to provide an additional 0.18 QALYs or 0.18 LYs compared to
treatment with VKA over a lifetime horizon (Table 2).
Costs associated with handling stroke and thromboembolic
events were lower in the apixaban treatment scenario compared to
the VKA treatment scenario (J14,113 vs. J14,904) (Table 2).
However, the overall anticoagulant treatment costs including the
drug acquisition costs, costs of routine care and INR monitoring
were higher with apixaban compared VKA (J6,092 vs. J3,449)
(Table 2). Accounting for all the aforementioned costs resulted in


















Cost of routine care J2,120 J2,067
Cost of INR monitoring J102 J1,018
Total costs J20,205 J18,353
VKA, vitamin K-antagonist; p.p., per patient; IS, ischemic stroke; HS, hemorrhagic stroke; SE, systemic embolism; ICH, intracranial hemorrhage; MB, major bleeding; GI,
gastrointestinal; CRNM, clinically relevant non-major; MI, myocardial infarction; INR, international normalized ratio.
doi:10.1371/journal.pone.0103974.t002
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Finally, the summarized lifetime health and economic conse-
quences of applying apixaban compared to VKA in 70-year old
patients in the Netherlands yielded a base-case ICER of J10,576
per QALY gained or J10,529 per LY gained (Table 3).
Sensitivity analyses
Figure 2 presents a tornado diagram illustrating the impact of
varying each of key input parameters on the ICER while holding
all the other model parameters fixed. The uncertainty around the
absolute stroke risk under apixaban, the risks of treatment
discontinuations under both apixaban and VKA and the risk of
ICH under VKA, showed the highest impact on uncertainty in the
estimated ICERs. In particular, when the absolute stroke risk or
treatment discontinuations risk under apixaban would reach the
upper limit of the 95% confidence interval (CI), ICERs would be
J33,426 and J27,103 per QALY gained, respectively. At risks
dropping to lower limits of 95% CIs, ICERs would fall to J4,268
or J5,086 per QALY gained, respectively. The uncertainty
around the risks of treatment discontinuations under VKA led to
comparable variation in estimated ICERs ranging from J4,236 to
J25,811 per QALY gained.
The results of 2,000 iterations in PSA are presented through an
incremental CE plane in Figure 3. The ellipsoid shape of this
incremental CE plane indicated a negative correlation between
incremental costs and incremental effects. Transforming the
results of a CE plane to CEACs shows that apixaban was cost-
effective at alternative willingness to pay (WTP) thresholds of
J20,000/QALY and J30,000/QALY in 68% and 72% of
simulations respectively (Figure 4). Accordingly, VKA was esti-
mated to be the preferred alternative over apixaban at the
aforementioned WTP thresholds in 32% and 28% of simulations
respectively.
The impact of different levels of INR control on the estimated
ICER was explored through scenario analyses. Specifically, the
level of INR control is applied for the estimation of the rates of IS,
ICH, other MB and CRNM bleeding and therefore can have an
indirect impact on the estimated ICER. Across the scenarios
investigated, the majority of the aforementioned rates was
estimated to be lower with apixaban compared to VKA. IS rate
with apixaban was estimated to be higher than with VKA (i.e.
1.316 and 1.159, respectively) only in the scenario assuming
allocation of patients in the range 52.38%#cTTR,66.02%.
Finally, the estimated ICER was in range from J27 to J12,662/
QALY or from J22 to J12,905/LY across the scenarios explored
(Table 4).
Discussion
This economic evaluation estimated the CE of apixaban
compared to VKA for prevention of stroke and other thrombo-
embolic events in patients with non-valvular AF in the Nether-
lands. Apixaban was shown to be a cost-effective alternative to
treatment with VKA with an ICER of J10,576/QALY or
J10,529/LY. Notwithstanding that both the Dutch-specific level
of INR monitoring (TTR=72.48%) and a weighted level of
baseline CHADS2 stroke risk were incorporated in this analysis,
the specific long-term health and economic benefits of treatment
with apixaban are evident. Those benefits correspond with a lower
number of stroke and thromboembolic events as well as a
generally better safety profile (i.e. less ICH and CRNM bleeding
events) that is associated with the use of apixaban when compared
to VKA. However, the number of other MBs was higher in the
apixaban treatment scenario compared to VKA scenario. This
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MBs between the two comparators and a higher number of
survivors in each model cycle that would be exposed to those risks
in the apixaban treatment scenario.
Yet, the base-case ICER was found to be below the Dutch
informal WTP threshold of J20,000/QALY in 68% of PSA
simulations mainly reflecting the uncertainty in the apixaban
absolute stroke risk and the risks of treatment discontinuations
under both comparators. The major impact of uncertainty in those
risks on both incremental effects and incremental costs was
visualized in univariate sensitivity analyses’ tornado diagram
(Figure 2) and PSA’s incremental CE plane (Figure 3). Specifical-
ly, the estimated ICERs in univariate and probabilistic sensitivity
Figure 2. Tornado diagram illustrating results from sensitivity analyses for apixaban vs. vitamin-K antagonists. Black bars denote
influence of the high value of the 95% confidence interval range and grey bars denote influence of the low value for parameters investigated. ICER,
incremental cost-effectiveness ratio; QALY, quality adjusted life year; ICH, intracranial hemorrhage; AF, atrial fibrillation; MI, myocardial infarction; MB,
major bleeding.
doi:10.1371/journal.pone.0103974.g002
Figure 3. Incremental cost-effectiveness plane. Incremental cost-effectiveness plane presents the incremental cost-effectiveness ratios of
apixaban compared to vitamin-K antagonists in patients with non-valvular atrial fibrillation, obtained through a probabilistic sensitivity analysis.
Points below the diagonal dotted and the full line represent simulations in which apixaban was a cost-effective alternative at a threshold of J30,000/
QALY and J20,000/QALY, respectively. QALY, quality adjusted life year; VKA, vitamin-K antagonists.
doi:10.1371/journal.pone.0103974.g003
Pharmacoeconomics of Apixaban for Stroke Prevention
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analyses, the specific shape of incremental CE plane and the
overall number of simulated ICERs below a certain WTP
threshold are mainly driven by the uncertainty in absolute stroke
risk and treatment discontinuations risk. Notably, the relevance of
the uncertainty in the apixaban absolute stroke risk can be directly
attributed to its impact on the occurrence of stroke events and
their related costs of treatment and reduced quality of life. In
particular, the influence of the risk of treatment discontinuations
can be indirectly explained by the choice of a second-line
treatment that would follow after those discontinuations. In this
analysis ASA was chosen to be a second-line treatment even
though it provides less protection from various thromboembolic
and bleeding events. Therefore, uncertainty in the risk of
treatment discontinuations would in the case of a higher level of
risk, lead to more patients being treated with ASA and
consequently to a higher number of stroke and thromboembolic
events.
Finally, the results of the scenario analyses examining the
impact of different levels of INR control were quite robust,
resulting in ICER estimates bellow J20,000/QALY in all the
scenarios.
Comparison with other studies
Findings of this analysis regarding the long-term health effects
and economic consequences of using apixaban compared to VKA
are similar to the results of other analyses studying apixaban in the
US setting [39]–[41]. Harrington et al. evaluated the use of
NOACs compared to warfarin and estimated an ICER of
$15,026/QALY for apixaban [39]. Furthermore, the use of
apixaban was reported to be a cost-effective alternative with
$11,400/QALY compared to warfarin in the study of Kamel et al
[40]. Finally, Lee et al. found apixaban to be a cost-saving option
compared to warfarin [41]. Differences in the observed ICERs
might be explained by different modelling assumptions and inputs
that were used. Also differences in economic consequences
associated with the use of anticoagulants could be attributed to
the variability in country-specific cost estimates and the choice of
study perspective (e.g. societal [40], [41]). Finally, differences in
the underlying patients’ characteristics, modes of INR control and
various modelling assumptions such as inclusion of multiple
recurrent events [41] or different comorbid health states (e.g.
transient ischemic attack [40]) could additionally hinder compa-
rability between the study results.
Strengths and limitations
Our study examines the potential use of apixaban for the
prevention of stroke and other thromboembolic events in patients
with non-valvular AF in the Dutch setting. Country-specific cost
estimates, nation-specific background mortality and conjoint
influence of the level of INR control and the allocation of baseline
CHADS2 stroke risk in Dutch population on the events rates were
implemented in this analysis. Furthermore, the impact of different
levels of INR control was examined in this study. Comparable to
similar CE studies, the health states of IS, SE, ICH, MI and
CRNM bleedings were incorporated in this analysis. Finally,
unlike other aforementioned analysis, utility estimates of stroke,
MI and SE were estimated to reflect the level of utility for joint
health states, using specific methodologies [42].
Our analysis has several limitations that may restrict the
interpretation of results in a broader context. One limitation might
be that the event rates incorporated in the decision model were
assumed to be constant through life even though they were based
on ARISTOTLE trial with an average follow-up of 1.8 years. This
assumption, however, was partly corrected by applying event-
specific rates that account for age-related increase in risk. In
addition, multiple thromboembolic events were not incorporated
in the decision model due to the lack of epidemiological evidence.
Incorporating multiple thromboembolic events could nevertheless
Figure 4. Cost-effectiveness acceptability curves for the treatment with apixaban and VKA in non-valvular atrial fibrillation. The
cost-effectiveness acceptability curve assesses the probability that the estimated incremental cost-effectiveness ratio is under a certain willingness to
pay threshold. VKA, vitamin-K antagonist; QALY, quality adjusted life year.
doi:10.1371/journal.pone.0103974.g004
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lead to a more favorable ICER which makes our analysis more
conservative. A further potential limitation in our analysis is the
assumption that a certain number of patients who experience ICH
or other MB as well as all patients that discontinue treatment for
reasons other than thromboembolic events, switch to a treatment
with ASA. Noticeably, second-line treatment with ASA will
provide a different level of protection from stroke and thrombo-
embolic events when compared to initially assigned anticoagu-
lants. In a real-life setting, patients might alternatively be switched
to other NOACs or VKAs. However, current guidelines have no
clear recommendations for the treatment following bleeding events
or treatment discontinuations. Finally, our analysis does not reflect
a societal perspective. In patients with non-valvular AF younger
than 65 years, incorporating a societal perspective is of major
importance given that this patient population encounters a
significant productivity loss. Accounting for the productivity loss
in the aforementioned patient population, would lead to even
more favorable ICERs.
Implications for practice and future research
Our findings showed apixaban to be a cost-effective alternative
to VKAs in the Dutch setting with 68% of chances if a willingness-
to-pay threshold is set to J20,000/QALY. Having in mind the
high cost of illness due to AF and associated comorbid events,
applying an effective and safe treatment in patients is of high
importance. In the ARISTOTLE and AVERROES trials
apixaban was shown to be a valuable alternative to VKAs and
ASA regarding the effectiveness and safety issues. However ‘‘real
life’’ long-term benefits of the use of apixaban as well as other
NOACs still need to be proven, primarily regarding the patients’
adherence to them [43]. Additionally, the regulations regarding
the choice of a second-line treatment in the case of adverse drug
reactions need to be more clearly specified.
Apixaban is a NOAC which was recently approved for use in
Europe, just after two other NOACs, rivaroxaban and dabigatran,
were introduced. Further investigation should be directed to
estimating comparative effectiveness and CE among the individual
NOACs in the Dutch setting.
Supporting Information
Table S1 Rates of events while on apixaban, VKA and
ASA used in estimating the transition probabilities in the
model. VKA, vitamin K-antagonist; ASA, acetylsalicylic acid; IS,
ischemic stroke; HR, hazard ratio; cTTR, clinic time in
therapeutic range; MI, myocardial infarction; ICH, intracranial
hemorrhage; MB, major bleeding; CRNM, clinically relevant non-
major; SE, systemic embolism.
(DOCX)
Table S2 Utility parameters applied in the model. AF,
atrial fibrillation; SE, systemic embolism; MI, myocardial
infarction; ICH, intracranial hemorrhage; MB, major bleeding;
CRNM, clinically relevant non-major; VKA, vitamin K-antago-
nist; ASA, acetylsalicylic acid. *Utility estimates that were available
only as single point estimates, were assumed to follow a beta
distribution with a 10% standard deviation of the mean. 1Utilities
were calculated based on the method for predicting utility for joint
health states by Bo Hu [42].
(DOCX)
Table S3 Cost parameters applied in the model. VKA,
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embolism; ICH, intracranial hemorrhage; GI, gastrointestinal;
CRNM, clinically relevant non-major; GP, general practitioner;
MI, myocardial infarction. {Cost estimates that were available
only as single point estimates, were assumed to follow a log-normal
distribution with a coefficient of variation equal to 0.25. 1Cost of
VKA was estimated as a weighted average cost of acenocumarol
and fenprocoumon based on their usage in the Netherlands [34]
"Stroke related costs were adjusted to fit the design of a decision
model. Specifically, acute and long-term one-month maintenance
costs were estimated. *Assumed to be equal to the cost of
pulmonary embolism. #Assumed to be the same as cost of acute
mild stroke ¥Assumed to be the same as cost of GI bleeds.
(DOCX)
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